Michael Ulz
Stock Analyst at Morgan Stanley
(4.67)
# 199
Out of 5,182 analysts
106
Total ratings
61.76%
Success rate
32.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $95 → $130 | $75.27 | +72.71% | 9 | Apr 21, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Upgrades: Overweight | $78 → $100 | $74.81 | +33.67% | 8 | Apr 21, 2026 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $21 → $15 | $8.77 | +71.04% | 9 | Mar 25, 2026 | |
| CABA Cabaletta Bio | Maintains: Overweight | $14 → $13 | $2.94 | +342.18% | 7 | Mar 24, 2026 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $50 → $47 | $17.39 | +170.27% | 4 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Equal-Weight | $29 → $7 | $5.46 | +28.21% | 2 | Mar 2, 2026 | |
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.70 | +186.00% | 3 | Jan 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $123 | $96.53 | +27.42% | 6 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $296.11 | +37.79% | 13 | Jan 30, 2026 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.87 | +181.85% | 3 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $98 → $102 | $30.00 | +240.00% | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $25 | $7.13 | +250.63% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $3.40 | +488.24% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.53 | +357.52% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $9.77 | +176.36% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.02 | +1,860.78% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.56 | +1,164.04% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $140 | $8.32 | +1,582.69% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $6.33 | -52.61% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $10.00 | +200.00% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $24.77 | +222.97% | 3 | Nov 3, 2017 |
Ionis Pharmaceuticals
Apr 21, 2026
Maintains: Overweight
Price Target: $95 → $130
Current: $75.27
Upside: +72.71%
Arrowhead Pharmaceuticals
Apr 21, 2026
Upgrades: Overweight
Price Target: $78 → $100
Current: $74.81
Upside: +33.67%
Karyopharm Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $21 → $15
Current: $8.77
Upside: +71.04%
Cabaletta Bio
Mar 24, 2026
Maintains: Overweight
Price Target: $14 → $13
Current: $2.94
Upside: +342.18%
Dyne Therapeutics
Mar 3, 2026
Maintains: Overweight
Price Target: $50 → $47
Current: $17.39
Upside: +170.27%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Equal-Weight
Price Target: $29 → $7
Current: $5.46
Upside: +28.21%
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.70
Upside: +186.00%
Mirum Pharmaceuticals
Jan 30, 2026
Maintains: Overweight
Price Target: $95 → $123
Current: $96.53
Upside: +27.42%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $296.11
Upside: +37.79%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.87
Upside: +181.85%
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $30.00
Upside: +240.00%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $7.13
Upside: +250.63%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.40
Upside: +488.24%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.53
Upside: +357.52%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $9.77
Upside: +176.36%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.02
Upside: +1,860.78%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.56
Upside: +1,164.04%
Jan 27, 2023
Maintains: Overweight
Price Target: $280 → $140
Current: $8.32
Upside: +1,582.69%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $6.33
Upside: -52.61%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $10.00
Upside: +200.00%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $24.77
Upside: +222.97%